ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Missouri » Hematology Oncology

Top Hematology Oncology Prescribers in Missouri

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ALI KHOJASTEH M.D.

Hematology Oncology

5,214

$911K

393
314 are 65+

4%
patients receiving schedule two controlled substances

Avg: 16%

5%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 17%

$175
Average prescription price

Avg: $382

JASWINDER SINGH MD

Hematology Oncology

3,022

$854K

337
249 are 65+

24%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 17%

$283
Average prescription price

Avg: $382

TAMARA HOPKINS M.D.

Hematology Oncology

2,989

$494K

242
170 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 17%

$165
Average prescription price

Avg: $382

LARRY ROSEN M.D.

Hematology Oncology

2,936

$907K

328
299 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 17%

$309
Average prescription price

Avg: $382

BURTON NEEDLES M.D.

Hematology Oncology

2,852

$2.08M

378
335 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 17%

$728
Average prescription price

Avg: $382

ROBERT ELLIS M.D.

Hematology Oncology

2,819

$1.8M

338
243 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

17%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 17%

$640
Average prescription price

Avg: $382

WILLIAM CUNNINGHAM M.D.

Hematology Oncology

2,712

$1.03M

407
316 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$381
Average prescription price

Avg: $382

MICHAEL TRENDLE MD

Hematology Oncology

2,541

$457K

213
179 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

15%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 17%

$180
Average prescription price

Avg: $382

LAVANYA TIRIVEEDHI M.D.

Hematology Oncology

2,538

$1.03M

341
267 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 17%

$405
Average prescription price

Avg: $382

HSIAO HU M.D.

Hematology Oncology

2,515

$553K

279
237 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

16%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 17%

$220
Average prescription price

Avg: $382

VIRAN HOLDEN MD

Hematology Oncology

2,333

$1.29M

285
230 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

16%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 17%

$554
Average prescription price

Avg: $382

UMASANKAR RAMADOSS MD

Hematology Oncology

2,139

$471K

224
201 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 17%

$220
Average prescription price

Avg: $382

GARY HOOS MD

Hematology Oncology

2,115

$451K

297
245 are 65+

13%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 17%

$213
Average prescription price

Avg: $382

JOSEPH MUSCATO MD

Hematology Oncology

2,079

$470K

223
191 are 65+

14%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 17%

$226
Average prescription price

Avg: $382

BASSEM CHAAR M.D.

Hematology Oncology

2,066

$588K

198
166 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

11%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 17%

$285
Average prescription price

Avg: $382

MANJULA RAJU MD

Hematology Oncology

1,941

$810K

265
199 are 65+

15%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 17%

$417
Average prescription price

Avg: $382

BRIAN OSGOOD M.D.

Hematology Oncology

1,866

$221K

199
174 are 65+

18%
patients receiving schedule two controlled substances

Avg: 16%

19%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 17%

$118
Average prescription price

Avg: $382

BROOKE GILLETT D.O.

Hematology Oncology

1,827

$744K

273
197 are 65+

23%
patients receiving schedule two controlled substances

Avg: 16%

10%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 17%

$407
Average prescription price

Avg: $382

RAJESH NAIR M.D

Hematology Oncology

1,726

$865K

250
195 are 65+

21%
patients receiving schedule two controlled substances

Avg: 16%

14%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 17%

$501
Average prescription price

Avg: $382

AKM HOSSAIN M.D., M.P.H.

Hematology Oncology

1,717

$545K

161
57 are 65+

19%
patients receiving schedule two controlled substances

Avg: 16%

9%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 17%

$317
Average prescription price

Avg: $382

JOHN FINNIE MD

Hematology Oncology

1,677

$1.07M

243
202 are 65+

16%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 17%

$640
Average prescription price

Avg: $382

CHRISTOPHER SIRRIDGE M.D.

Hematology Oncology

1,611

$421K

173
114 are 65+

31%
patients receiving schedule two controlled substances

Avg: 16%

21%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 17%

$261
Average prescription price

Avg: $382

DAVID CROY MD

Hematology Oncology

1,610

$315K

189
148 are 65+

12%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 17%

$196
Average prescription price

Avg: $382

ARIF BARI M.D.

Hematology Oncology

1,596

$377K

191
149 are 65+

9%
patients receiving schedule two controlled substances

Avg: 16%

13%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 17%

$236
Average prescription price

Avg: $382

SHABBIR SAFDAR M.D

Hematology Oncology

1,591

$2.82M

215
156 are 65+

10%
patients receiving schedule two controlled substances

Avg: 16%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

39%
prescriptions for brand name drugs

Avg: 17%

$1771
Average prescription price

Avg: $382

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank